Leerink Partners maintains Tenet Healthcare at Outperform, raises price target to $342 from $309

Leerink Partners kept its Outperform rating on Tenet Healthcare and raised its price target to $342 from $309, citing a 25.2% upside from the Oct 30 close of $273.25. Recent analyst price targets for the company range from $304 to $321.

Original reporting
Published Nov 2, 2026, 7:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Tenet Healthcare at Outperform, raises price target to $342 from $309 — source image
Decision brief

The 30-second read

$THCBullishMed
01

Why it matters

The price target increase signals confidence in Tenet's near‑term performance, potentially prompting short‑term buying.

02

Market read

Analyst target raise provides a fresh catalyst for THC, offering a modest trading edge.

03

What to watch

Potential regulatory or reimbursement risks not addressed in the note.

Relevance 6/10Novelty 6/10Timing: today

Background

Tenet Healthcare (THC) is a U.S. hospital operator; analyst upgrades can move its stock.

Company-level read

Ticker impact

$THCBullishMedium confidence
Context

Leerink Partners raised Tenet Healthcare's price target to $342 from $309.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 25% upside from current price, which may attract buying interest.

Market effects

May lift sentiment in the healthcare services sector.

Limited to U.S. markets where Tenet trades.

Low

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Tenet Healthcare

    U.S. hospital operator

  • Leerink Partners

    Equity research firm issuing the target raise

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.